Objective: To estimate the incidence and mortality rates, and their evolution over time,
P
rimary Sjögren syndrome (pSS) is a systemic autoimmune disorder characterized by an inflammatory infiltrate and progressive dysfunction of exocrine glands, particularly the lachrymal and salivary glands. 1 Cardinal symptoms include mouth and eye dryness, marked fatigue, and widespread pain, which have a profound effect on the quality of life of patients with pSS. 2 These symptoms are nonspecific and can occur with many other conditions. 3, 4 Up to one-third of patients also experience extraglandular inflammatory involvement, including polysynovitis, neuropathy, and inflammatory lung disease. [5] [6] [7] The etiology of pSS is not well understood 8 and probably includes environmental triggers in genetically predisposed individuals, as illustrated by its familial aggregation 9 and predisposing genetic variants. 10 It mainly affects middle-aged women, with a strong sex bias potentially explained by an X chromosome dose effect. 11 Primary SS occurs as a primary disorder, and secondary SS may occur with other systemic inflammatory diseases, such as rheumatoid arthritis and systemic lupus erythematosus. 12, 13 Primary SS may be associated with malignancies, especially nonHodgkin lymphoma.
There are no specific diagnostic tests for pSS. To facilitate study of the disease and improve uniformity of the patient populations in clinical studies, researchers have developed classification criteria based on the signs and symptoms and diagnostic tests used in evaluating patients with suspected SS. The coexistence of 2 different sets of classification criteria for pSS (the 2002 AmericanEuropean Consensus Group [AECG] 15 and the 2012 American College of Rheumatology [ACR] 16 ) justified new consensual criteria, [17] [18] [19] which have been developed through an ACReEuropean League Against Rheumatism (EULAR) collaboration and were recently published. 20, 21 The epidemiology of pSS is poorly defined. 22 , 23 We recently reported that the 2015 prevalence of pSS in Olmsted County, Minnesota, was 10.3 per 10,000 inhabitants by physician diagnosis but only 2.2 per 10,000 according to the classification criteria. 24 Estimates of pSS incidence also vary considerably depending on the population studied and the methods used for case detection and ascertainment, with published incidence rates ranging from 3.1 to 10.7 cases per 100,000. 25, 26 The only incidence data available in the United States were published by our group, which reported an average incidence of 3.9 per 100,000 for 1976 through 1992 27 and 5.1 per 100,000 for 1976 through 2005, 28 suggesting a progressive increase of the incidence of the disease over time. It is unclear whether patients with pSS have an increased risk of mortality compared with the general population. 29 The objective of this study was to estimate the incidence and mortality rates, and their evolution over time, of physician-diagnosed pSS in residents of Olmsted County.
METHODS

Case Identification and Ascertainment
The study population included patients with incident pSS diagnosed in Olmsted County, a county with 113,306 adult (age !18 years) inhabitants as of January 1, 2015. This population is well suited for investigation of the epidemiology of pSS because of the availability of comprehensive medical record information for the entire population. 30, 31 Potential cases were selected based on diagnostic codes for SS, autoantibody positivity (anti-Ro/SSA or anti-La/SSB), sicca syndrome, and keratoconjunctivitis sicca using the resources of the Rochester Epidemiology Project. This is a medical records linkage system that allows ready access to the complete (inpatient and outpatient) records from all health care providers for the local population, including Mayo Clinic and its affiliated hospital, the Olmsted Medical Center and affiliated community hospital, local nursing homes, and a few private practitioners. 32 This system ensures virtually complete clinical information on all clinically recognized cases of pSS in Olmsted County residents. For the current update of pSS incidence, potential cases were all residents of Olmsted County at the time of their diagnosis, made between January 1, 2006, and December 31, 2015. These new cases were analyzed together with a previously reported incident pSS cohort including patients first diagnosed from 1976 through 2005 (n¼111) from the same population. 28 In addition to screening by diagnostic codes for SS and relevant autoantibodies, 50 randomly selected patient records with diagnostic codes of xerostomia and 50 with keratoconjunctivitis sicca but without a diagnosis of SS or relevant autoantibodies were also screened to assess whether any additional cases of pSS case were missed using the other codes. Because no patients with incident pSS were identified in these samples, the probability of missed cases is very low.
All individual clinical records from patients selected during the first screening phase were reviewed. All patients with a definite physician diagnosis of pSS were included. Almost all diagnoses were made or confirmed by rheumatologists. Cases of uncertain diagnosis and those with secondary SS were excluded. Collected data included date of first pSS diagnosis, age, sex, race/ethnicity, smoking status, presence of dry eyes and dry mouth, serologic tests (anti-Ro/SSA, anti-La/ SSB, antinuclear antibodies, and rheumatoid factor), presence of hypergammaglobulinemia, and results of diagnostic tests if performed (eg, the Schirmer test, ocular surface staining, salivary scintigraphy, parotid sialography, unstimulated salivary flow measurement, and minor salivary gland biopsy).
The 2002 AECG and 2012 ACR classification criteria were applied to all physiciandiagnosed cases. Systemic involvement was analyzed at the time of the diagnosis in patients diagnosed from 2006 through 2015 according to the EULAR SS Disease Activity Index (ESSDAI), [33] [34] [35] with no or low systemic activity defined as an ESSDAI of less than 5, moderate activity as an ESSDAI of 5 to 13, and high activity as an ESSDAI of 14 or more. 36 
Statistical Analyses
Descriptive statistics (means, percentages, etc) were used to summarize the data.
Comparisons of patient characteristics between time periods were performed using c 2 and rank sum tests. Age-and sex-specific incidence rates for adults (age !18 years) were calculated using the number of incidence cases as the numerator and population estimates based on decennial census counts as the denominator, with linear interpolation to estimate population size for intercensal years. Annual incidence rates were illustrated using a 3-year centered moving average. Overall rates were age and sex adjusted to the 2010 US white population. Ninety-five percent CIs were computed for incidence rates assuming (14) 17 (28) 32 (19) .02 Met the 2012 ACR criteria 20 (18) 16 (26) 36 (21) . that the observed number of cases follows a Poisson distribution. Poisson regression models with smoothing splines to allow for nonlinear effects were used to evaluate time trends in incidence rates.
Survival after the diagnosis of pSS was estimated using Kaplan-Meier methods. Observed and expected survival rates were compared using the log-rank test, where expected survival was based on the sex and age of the study population and on death rates from the Minnesota white life tables. The standardized mortality ratio, the ratio of observed number of deaths to the expected number, was estimated and a 95% CI was obtained assuming that the observed number of deaths follows a Poisson distribution. Analyses were performed using statistical software programs (SAS version 9.4; SAS Institute Inc and R version 3.1.1; R Foundation for Statistical Computing).
RESULTS
Characteristics of the Cohort
From 2006 through 2015, 61 new patients were diagnosed as having incident pSS in Olmsted County, and these patients were analyzed together with the incident cases diagnosed from 1976 through 2005. One patient, aged 17 years at diagnosis, was excluded from incidence calculations but was included in the survival analysis.
Of the 172 patients, 151 (88%) were women and 161 (94%) were of white race ( Table 1 ). The mean AE SD age at diagnosis was 58.3AE16.7 years. Most patients (94 of 162 [58%]) were never smokers. More patients reported dry eye symptoms (n¼156, 91%) than dry mouth symptoms (n¼144, 84%). There were no significant differences concerning these general characteristics between patients diagnosed before or after 2005. Features of systemic involvement at diagnosis were retrospectively collected for patients diagnosed from 2006 through 2015 using the ESSDAI (Table 2 ). Most patients (70%) had no or low systemic disease activity at incidence, 21% had moderate activity, and 8% had high activity. The median (range) ESSDAI score was 1 (0-23). Among the different ESSDAI domains, most of the systemic activity was scored for the biological domain (in 26 patients), with only 12 patients scored for the glandular, 6 for the peripheral nerve, and 3 for the articular domains. Of the objective tests used by physicians to make a pSS diagnosis, serologic studies were the most frequently performed (Table 1) . When performed, rheumatoid factor was positive in 53% of patients, antinuclear antibodies in 71%, anti-Ro/SSA in 74%, and anti-La/SSB antibodies in 56%. Hypergammaglobulinemia was present in 50% of patients with available data. Objective tests to assess for sicca symptoms were rarely performed. Ocular objective procedures (the Schirmer test or ocular surface staining) were performed in 61 patients, and results were positive in 53 (87%). Salivary gland morphologic or functional tests (salivary scintigraphy, parotid sialography, or unstimulated salivary flow) were performed in 65 patients, and results were positive in 15 (23%). Minor salivary gland lip biopsy was performed in only 21 patients, and results were positive in 12 (57%). Comparing the 2 periods, physicians more often used serologic tests, especially anti-Ro/SSA and anti-La/SSB antibodies, to diagnose the disease after 2005. Accordingly, only 32 patients (19%) met the AECG criteria for classification of pSS, and 36 (21%) fulfilled the ACR criteria.
Analysis of pSS Incidence Over Time and Impact of Seasonality
The overall age-and sex-adjusted annual incidence of pSS was 5.8 per 100,000 population 18 years and older during the 40-year period covered by the study (Table 3 ). The incidence was 2 to 7 times higher in women compared with men in the different age classes (5.9 times higher on average), and it increased progressively with age, culminating at 19.6 per 100,000 in women aged 65 to 74 years, with a slight decline thereafter to 15.9 per 100,000 in women 75 years and older.
There was some fluctuation in the annual incidence of pSS, with higher values around 1990, 2005, and 2015. Overall, however, there was a progressive increase of pSS incidence over time (P¼.005) (Figure, A) . The overall age-and sex-adjusted incidence per 100,000 population was 4.2 (95% CI, 2. No effect of seasonality on disease incidence was observed, with an age-and sex-adjusted incidence rate (95% CI) per 100,000 population of 1.6 (1.1-2.1) during winter, 1.1 (0.7-1.5) during spring, 1.6 (1.1-2.1) during summer, and 1.5 (1.0-1.9) during fall (P¼.38 for the 4-season comparison) (Figure, B) .
Mortality of Patients With pSS Compared With the General Population
There were 52 deaths in the 172 patients (30%). Compared with the general population, in which approximately 45 deaths would be expected, the standardized mortality ratio for patients with incident pSS from 1976 through 2015 was 1.15 (95% CI, 0.86-1.50) (Figure, C) . No evidence of a time trend in survival according to year of diagnosis was found (P¼.90) (data not shown). Overall and 5-, 10-, and 20-year survival rates (95% CIs) were 56.7% (46.6%-68.9%), 93.7% 
DISCUSSION
This study reports estimates of the pSS incidence and mortality rates and their evolution over 40 years in a geographically well-defined region in the United States. The estimated incidence of pSS in Olmsted County from 1976 through 2015 was 5.8 per 100,000, with a significant progressive increase over time. Mortality rates of patients with pSS were similar to expected rates in the general population.
Better description of the epidemiology of pSS is important for public health stakeholders, regulating agencies, and drug companies. To date, no disease-modifying drug has been proved to be effective in improving pSS symptoms and in changing the natural course of the disease, as all the results of published large randomized controlled trials are negative. [37] [38] [39] These trial failures could be explained by design issues and outcome definitions. 40, 41 Treatment algorithms are currently based on expert opinion, usually by analogy to other systemic autoimmune diseases. [42] [43] [44] However, recent years have witnessed an increase in interest of pharmaceutical companies for developing new drugs for treating the disease, and more than 10 industry-sponsored randomized controlled studies are currently ongoing. 45 Hopefully, some of these innovative drugs tested in the disease will demonstrate their efficacy, and better knowledge of the number and characteristics of patients in the general population who could potentially benefit from these drugs will be of major importance at the time of their commercialization.
All the previous studies reporting pSS incidence worldwide are summarized in Table 4 . Our incidence rate is in the range of what was described in those previous studies, despite differences in study design and case definitions. Strengths of the present study include the broad screening method, using the Rochester Epidemiology Project medical records linkage system, and allowing full access to a performant coding system and to all the individual medical records of the screened patients, which resulted in exhaustive case detection and ascertainment in the general population living in Olmsted County. Most of these other studies used hospitalbased medical record searches, 25, 26, 46, 47 but it is likely that some patients with mild presentation not requiring specific therapies are diagnosed and followed outside of the hospital setting and are, therefore, missed by such case detection strategies. The study by Weng et al 48 in Taiwan used an administrative database search with no case ascertainment, which could be biased by coding errors and, therefore, false diagnoses.
The case ascertainment method in this study was based on definite physician diagnosis of pSS. Even if not standardized, this reflects how the disease is actually diagnosed, and therefore treated, in routine practice in a community setting. Using only administrative coding systems without analyzing actual medical data from the clinical records may lead to the inclusion of patients who do not have the diagnosis and failure to detect actual patients.
As demonstrated in the present study, current classification criteria for pSS are not applicable to epidemiologic studies in a community-based setting because physicians in Olmsted County do not use several of the tests included in the different versions of the classification criteria (mainly functional salivary and ocular tests and salivary gland biopsy) to diagnose the disease. The main explanation for not fulfilling the criteria was that the required tests were not performed, and not that the results were negative. Of note, a similar observation was made in previous population-based pSS studies. In the prevalence study by Maldini et al, 51 a substantial proportion of patients received a clinical diagnosis of pSS but did not fulfil the AECG criteria because oral/ocular tests were not performed, and the authors used "enlarged" criteria to define pSS cases.
The low number of patients who underwent a salivary gland biopsy in the present cohort probably indicates that treating physicians consider that patients without autoantibodies (anti-Ro/SSA or anti-La/SSB but also antinuclear antibody or rheumatoid factor) do not actually have pSS. The main therapies offered to patients with sicca symptoms with or without pSS are directed toward management of were excluded from this table because they used a random sample of the same population, including the same years, as the study by Weng et al. 48 dryness, including tear and saliva substitutes. Therefore, physicians may not consider it clinically useful to perform invasive diagnostic tests such as salivary gland biopsy if the results of these tests would not affect clinical decisions regarding diagnosis and management. However, even if "seronegative" patients with pSS probably have a lower risk of lymphoma development, 52 they have symptoms severe enough to require medical attention. 53 Besides its diagnostic value, salivary gland biopsy also gives important prognostic information, as patients with higher focus scores or ectopic germinal centers have a higher risk of systemic complications and lymphoma development. [54] [55] [56] Therefore, minor salivary gland biopsy should be considered in every patient with suspected pSS.
Several reasons could explain the progressive increase of pSS incidence over time seen in this study. Aging of the general population is not a factor because all incidence estimates are age and sex adjusted to the general population. Interestingly, the general characteristics of patients diagnosed as having pSS in Olmsted County did not change over time. Physicians could be more aware of the diagnosis in the recent years compared with the early years (1970s-1980s) of the study period. The greater availability of anti-Ro/SSA and anti-La/SSB antibody testing over the 40 years of this study could also have contributed to the increased incidence over time, facilitating a diagnosis in those with milder disease. Patients may seek medical care more often for subjective symptoms that impair their quality of life but may still be considered benign. Changes in lifestyle and environmental exposures could also lead to a real increase of the number of individuals developing this autoimmune disease.
The mortality rate in patients with incident pSS in Olmsted County is not higher than that in the general population. Previous studies have shown that subgroups of patients with pSS have decreased survival rates, especially patients with high systemic disease activity 57 and, notably, patients who develop severe systemic involvement, such as cryoglobulinemic vasculitis, 58 or lymphoma. 59 However, those severe presentations are rare in patients with incident pSS and do not affect overall survival. Systemic involvement in the present cohort was analyzed at the time of diagnosis based on retrospective medical record review, which could lead to an underevaluation of the ESSDAI score, especially its biological domain, if tests required for the scoring were not performed (such as measurement of cryoglobulin, IgG, or complement levels).
CONCLUSION
The average annual incidence of physiciandiagnosed pSS in Olmsted County was 5.8 per 100,000 population, with a progressive increase during the 40 years covered by the study. Current classification criteria do not perform well to study the epidemiology of pSS in a community setting. Overall survival of patients with pSS was not different from that of the general population. 
